Outsourcing in Clinical Trials Nordics 201417-18 September 2014, Copenhagen, Denmark
With healthcare innovation and growth being considered a top priority for the Nordic region, clinical trials are regarded as a key aspect of delivery innovation, with governments incentivising and rewarding such efforts. One of the key considerations for the Nordics is the need for collaboration. Furthermore, with the increased rewards for innovation, the industry is looking to increase R&D activity, which in turn means there will be considerable development within clinical trials. Against this backdrop, OCT Nordics will allow companies from within this Nordic-specific hub to come together and discuss proven strategies to improve and create partnerships within clinical trials and medical devices.
Alongside the biopharmaceutical outsourcing sessions, we will also include unique medical device-specific sessions in a separate stream covering: medical device outsourcing, patient recruitment and new regulations (e.g. MDD). This year’s event will have more of an operational focus and bring together senior industry representatives to discuss the latest challenges within clinical outsourcing and medical device-related challenges such as: improved vendor communication strategies, vendor sourcing/selection, budgeting and contracting, oversight and management, patient recruitment, risk-based monitoring and feasibility plans.
Outsourcing in Clinical Trials Nordics 2014 promises to be a highly engaging meeting and will present a unique platform for discussion alongside thought-sharing on innovative strategies within outsourcing models in this ever-growing region.
On behalf of World Courier and Arena International, we wish to cordially invite all attendees at the upcoming Outsourcing in Clinical Trials Nordic Conference to a first evening drinks reception to be held immediately following the conclusion of Day 1 activities.
Whether you are a senior professional in a global pharmaceutical company or a smaller company looking to expand, access to insight and knowledge about the latest pharmaceutical trends is vital.
The Outsourcing Clinical Trial series is growing every year. View the full list of upcoming events to make sure you don’t miss any news. The list of websites will be updated as soon as new events are live so check back regularly
Primary delegates for this event are those with responsibility for clinical outsourcing in biotech and pharma companies within the Nordic region.
We are always happy to see photos taken at our events! If you have any you would like to submit, please email firstname.lastname@example.org The Arena Team
Testimonials from other events in our Outsourcing in Clinical Trials Series
Agios Pharmaceuticals has started a Phase I/II multicentre trial of AG-221 in patients with advanced solid tumours, including gliomas, as well as angioimmunoblastic T-cell lymphoma (AITL) that carry an isocitrate dehydrogenase-2 (IDH2) mutation.
US-based RegeneRx Biopharmaceuticals has received approval from the US Food and Drug Administration (FDA) to start Phase III trials to evaluate RGN-259 preservative-free eye drops to treat patients with neurotrophic keratopathy (NK), an orphan diseas…
Theravance has reported positive results from a third lung function trial of Anoro Ellipta (umeclidinium /vilanterol, UMEC/VI) with the LAMA tiotropium, administered in the HandiHaler inhaler, in patients with chronic obstructive pulmonary disease (C…
Regeneron Pharmaceuticals and Sanofi have started dosing patients in a Phase III clinical trial of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, in adults with moderate-to-severe atopic dermatitis (AD).
US-based Allegro Ophthalmics has started patient enrolment in Phase II trial designed to evaluate the safety and efficacy of Luminate, previously known as ALG-1001, in patients with diabetic macular edema (DME).
US-based biopharmaceutical firm Epizyme has reported positive pre-clinical data from its Phase I/II trial of EPZ-6438 (E7438), its oral, small molecule inhibitor of EZH2, in models of synovial sarcoma, a soft tissue sarcoma that typically affects you…